NCT03006432.

Trial name or title	ASE III randomised trial to evaluate folfox with or without docetaxel (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago‐gastric carcinoma (GASTFOX)
Methods	Phase 3 Allocation: Randomised Intervention Model: Parallel assignment Masking: No masking Primary Purpose: Treatment
Participants	N = 506 Gastric or gastro‐oesophageal junction adenocarcinoma (all Siewert), histologically proven (on primary tumour or metastatic lesion), HER2 negative (positive HER2 status is defined by a positive IHC test of 3+ or IHC of 2+ with positive FISH) Metastatic or non‐resectable (locally advanced) disease
Interventions	Active Comparator: FOLFOX Cycles every 15 days until progression disease Experimental: TFOX Cycles every 15 days until progression disease Interventions: Drug: oxaliplatin Drug: 5Fluorouracil bolus Drug: 5Fluorouracil continuous Drug: docetaxel Drug: folinic Acid
Outcomes	Progression‐free survival [Time frame: 12 months after last randomisation] Overall survival toxicity events (adverse events) according to NCI‐CTC v4.0 [Time frame: 12 months after last randomisation] Objective response rate [Time frame: 12 months after last randomisation] Toxicity events according to NCI‐CTC v4.0 [Time frame: 12 months after last randomisation]
Starting date	December 2016
Contact information	Contact: Marie MOREAU +33 (0)380393404 marie.moreau@u‐bourgogne.fr
Notes	PRODIGE 51